Guardant Health, Inc.
NASDAQGH put-call ratio surges to 1.15, highest in four weeks, signaling heavy options demand ahead of earnings.
Snapshot as of 6 Aug 2026
Guardant Health heads into its July 30 earnings print with a fresh wave of analyst target increases, a stock up 30% over the past month, and options traders growing noticeably more cautious about what comes next. The…
Guardant Health closes the week at $150.03 — up 15% in seven days — with its co-founder selling aggressively into the strength and analysts still racing to catch up with the move. The insider story is the clearest…
Guardant Health enters the final week of June with a rare degree of Street alignment — multiple bellwether firms lifting targets in quick succession — even as short sellers maintain a meaningful 10% position in the…
Guardant Health has surged 22% in a week and 35% in a month — and the company's own executives are using the run-up to sell. The insider activity is the standout this week. On May 20, founder and CEO Amirali Talasaz…
Guardant Health enters the back half of May with short sellers quietly backing away and analysts nudging targets higher — a combination that frames a more constructive backdrop heading into the June 17 Q1…
Guardant Health heads into its May 7 Q1 2026 earnings print with options positioning flashing the most bullish signal in months — a sharp contrast to how the stock was positioned just two weeks ago. The options market…
GH heads into its April 30 Q1 earnings release with short sellers retreating sharply — yet the stock keeps falling anyway. The clearest signal in the data is the divergence between short interest and price. Shorts…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for GH — free to start on ORTEX.
Sign up for free →Open GH on ORTEX